WuXi AppTec
无锡药明康德
Executive Summary
WuXi AppTec is the single largest BIOSECURE exposure point in the US biotech supply chain. As the world's largest pharmaceutical CRO/CDMO by client count, WuXi provides contract research, manufacturing, and testing services to an estimated 6,000+ pharmaceutical and biotech companies globally, including the majority of the top 20 pharma companies. 34 US-listed companies have explicitly named WuXi in BIOSECURE-related SEC filings. While WuXi was removed from the enacted BIOSECURE Act's named entity list (unlike BGI), it remains under sustained congressional pressure and could be designated as a BCC via OMB's Category B process when the list is published by December 2026. Ge Li, the Columbia-trained chemist who founded WuXi in 2000, controls approximately 25% of voting rights through a complex holding structure spanning Cayman, BVI, and mainland China entities.
Structure: Complex multi-jurisdictional structure with Cayman holding companies controlling mainland China operating entities. WuXi AppTec (2359.HK) is the parent, with separate listed biologics arm WuXi Biologics (2269.HK) and recently spun-off ADC specialist WuXi XDC (2268.HK). Structure appears designed for international capital access rather than VIE requirements, but multiple offshore layers will complicate due diligence.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Ge Li 李革 | Chairman & CEO | PhD Organic Chemistry, Columbia University; BS, Peking University | |
Minzhang Chen 陈民章 | Co-CEO | PhD, University of North Carolina; MBA, Kellogg School of Management | |
Zhisheng Chen 陈智胜 | CEO, WuXi Biologics | PhD, University of Rhode Island |
Ownership & Shareholder Structure
WuXi AppTec → WuXi Biologics
WuXi AppTec holds ~52% indirect stake in WuXi Biologics through WuXi Biologics Holdings Ltd.
WuXi AppTec → Pfizer
WuXi AppTec provides CDMO services to Pfizer. Key API manufacturing relationship.
WuXi AppTec → Asymchem Laboratories
Compete for Big Pharma CDMO contracts. Both under congressional pressure.
GenScript Biotech → WuXi AppTec
GenScript gene synthesis competes with WuXi AppTec Genomics division.
Ge Li (Individual) → WuXi AppTec
Ge Li and spouse Liu Zhaomei collectively control ~25% of WuXi AppTec through multiple holding companies including HKSCC Nominees and direct shareholding. Source: HKEX disclosure of interests.
Subsidiaries & Affiliates(16)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
WuXi AppTec (Shanghai) Co., Ltd. 药明康德新药开发有限公司 | operating | mainland china | Drug R&D services, chemical synthesis, biological testing. Primary discovery chemistry hub. | CDMO | DIRECT |
STA Pharmaceutical Co., Ltd. 合全药业股份有限公司 | operating | mainland china | Small molecule API and drug product CDMO. One of the largest API manufacturers serving US biotechs. Major Pfizer and Lilly supplier. | CDMO | DIRECT |
WuXi AppTec (Tianjin) Co., Ltd. 药明康德(天津)有限公司 | operating | mainland china | Drug discovery and development services. | CDMO | DIRECT |
WuXi AppTec (Wuhan) Co., Ltd. 药明康德(武汉)有限公司 | operating | mainland china | Drug discovery and testing services. | CDMO | DIRECT |
WuXi AppTec (Suzhou) Co., Ltd. 药明康德(苏州)有限公司 | operating | mainland china | Preclinical and clinical development services. | CDMO | DIRECT |
WuXi AppTec (Nantong) Co., Ltd. 药明康德(南通)有限公司 | operating | mainland china | Drug product manufacturing. | CDMO | DIRECT |
WuXi AppTec (Changzhou) Co., Ltd. 药明康德(常州)有限公司 | operating | mainland china | API manufacturing facility. | CDMO | DIRECT |
WuXi AppTec (Qidong) Co., Ltd. 药明康德(启东)有限公司 | operating | mainland china | Large-scale API production facility. | CDMO | DIRECT |
WuXi AppTec Genomics 药明康德基因科技有限公司 | operating | mainland china | Gene synthesis and genomics services. Handles DNA/RNA synthesis for global clients. | CDMOGEN | DIRECT |
WuXi Testing (Shanghai) 药明康德检测(上海)有限公司 | operating | mainland china | Bioanalytical and safety testing services. | CDMO | DIRECT |
WuXi Advanced Therapies | operating | us | Cell and gene therapy CDMO. Philadelphia, PA. Supports US biotech CGT programs. | CDMO | DIRECT |
STA Pharmaceutical (US) | operating | us | US-based API and drug product operations. San Diego, CA. | CDMO | DIRECT |
WuXi AppTec (Germany) GmbH | operating | us | European operations hub. Munich, Germany. | CDMO | DIRECT |
Crelux GmbH | operating | us | Structural biology and protein crystallography services. Munich, Germany. Acquired 2018. | CDMO | DIRECT |
WuXi Biologics (Cayman) Inc. 药明生物技术有限公司 | offshore | cayman | Biologics CDMO holding company. HKEX:2269. ~52% owned by WuXi AppTec. Revenue >B. | CDMO | DIRECT |
WuXi XDC Cayman Inc. 药明合联生物技术有限公司 | offshore | cayman | ADC and bioconjugate CDMO. HKEX:2268. Spun off from WuXi Biologics Nov 2023 IPO. | CDMO | DIRECT |
Corporate Events
35 US Biotechs Disclose WuXi BIOSECURE Supply Chain Exposure in SEC Filings
35 US public companies have disclosed WuXi AppTec as a BIOSECURE risk factor across 292 SEC filings (10-K, 10-Q, 8-K). Companies include: Structure Therapeutics, ArriVent BioPharma, Spyre Therapeutics, Cabaletta Bio, Recursion Pharmaceuticals, Oruka Therapeutics, Tectonic Therapeutic, Iovance Biotherapeutics, Zenas BioPharma, Whitehawk Therapeutics, Jade Biosciences, Crescent Biopharma, Janux Therapeutics, Dianthus Therapeutics, EyePoint Pharmaceuticals, Kyverna Therapeutics, iTeos Therapeutics, Terns Pharmaceuticals, Cytek Biosciences, Curis, ImageneBio, Arcus Biosciences, Septerna, Bicara Therapeutics, Apogee Therapeutics, Viridian Therapeutics, Upstream Bio, 89bio, Akebia Therapeutics, Invivyd, Pasithea Therapeutics, Maze Therapeutics, Xilio Therapeutics, Zura Bio
BIOSECURE Impact: CRITICAL. If WuXi is designated BCC, 35+ US biotechs face immediate supply chain disruption. This is the strongest evidence of systemic WuXi dependency in the US biotech sector.
BIOSECURE Act signed — WuXi NOT on initial BCC list
NDAA Sec. 851 signed into law. Unlike the original House bill, WuXi entities are NOT named as BCCs. BCC designation now depends on OMB interagency process (Category B). WuXi stock rallied 15% on the news.
BIOSECURE Impact: Reduces but does not eliminate risk. WuXi remains under 'congressional pressure' and could be designated via Category B when OMB publishes the BCC list by Dec 2026.
US House Select Committee on CCP targets WuXi
House Select Committee on the CCP included WuXi AppTec and WuXi Biologics in the original BIOSECURE Act draft. Named alongside BGI as 'biotechnology companies of concern.'
BIOSECURE Impact: Direct. Original bill named WuXi entities explicitly. Final enacted version (Dec 2025) removed named companies in favor of OMB designation process.
WuXi XDC IPO on HKEX
WuXi Biologics spun off its ADC/bioconjugate business as WuXi XDC (2268.HK). Raised ~$420M. Seen as pre-emptive move to isolate ADC business from potential BIOSECURE impact on the parent.
BIOSECURE Impact: Creates structural separation that may complicate BCC subsidiary analysis under Category C.
Clinical Trials(50 total)
4
Phase 3
2
Phase 2
1
Phase 1
5
Other
7
NA
1
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06890143 | Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks | Ph.3 | RECRUITING | 44 |
| NCT07039604 | Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China | RECRUITING | 200 | |
| NCT06570291 | Mesenchymal Stem Cells, Sodium Hyaluronate Injection | Ph.3 | RECRUITING | 520 |
| NCT06924190 | Budiair® 200ug/puff inhalation aerosol, budesonide 200ug/puff inhalation aerosol | NA | COMPLETED | 32 |
| NCT06704581 | 5 mg BGM0504 injection, 10 mg BGM0504 injection administered subcutaneously (SC) once a week, 15 mg BGM0504 injection, BGM0504 placebo | Ph.3 | RECRUITING | 620 |
| NCT05996562 | Pulmonary Artery Denervation | NA | COMPLETED | 30 |
| NCT06392646 | self-management education program | NA | ACTIVE NOT RECRUITING | 34 |
| NCT06720129 | the modified pressure-reducing fixation protective nasal strip, Standard care alone | NA | COMPLETED | 60 |
| NCT06194188 | Subcutaneous injection of CU-20401 | Ph.2 | COMPLETED | 108 |
| NCT06152783 | Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study | UNKNOWN | 578 | |
| NCT06240767 | Granulocyte infusion | Ph.1 | UNKNOWN | 18 |
| NCT06051669 | iLivTouch, FibroScan | UNKNOWN | 418 | |
| NCT06404528 | Blood glucose stress combined with low-dose chemotherapy | NA | RECRUITING | 300 |
| NCT06212882 | Lower concentration and lower volume contrast agent group | UNKNOWN | 2,100 | |
| NCT05794204 | RMP-A03 - Dose 1, RMP-A03 - Dose 2, RMP-A03 Placebo | Ph.2 | COMPLETED | 77 |
| NCT05793892 | Lidocaine tetracaine cream | Ph.3 | COMPLETED | 286 |
| NCT05699811 | MSC-IFNα, Nab paclitaxel, Cyclophosphamide, Anti-PD-1 monoclonal antibody | Ph.1, Ph.2 | RECRUITING | 40 |
| NCT05253716 | ONS | NA | RECRUITING | 696 |
| NCT05330923 | Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease | RECRUITING | 200 | |
| NCT05253222 | retrograde image by colonic TET | NA | UNKNOWN | 60 |
Showing 20 of 50 trials
Top Publications (by citations)
Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions.
Ruiz-Castillo P, Buchwald SL.
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG.
Deep learning enables rapid identification of potent DDR1 kinase inhibitors.
Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD, Asadulaev A, Volkov Y, Zholus A, Shayakhmetov RR, Zhebrak A, Minaeva LI, Zagribelnyy BA, Lee LH, Soll R, Madge D, Xing L, Guo T, Aspuru-Guzik A.
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, Humeidi R, Peck D, Wu X, Tang AA, Wang VM, Bender SA, Lemire E, Narayan R, Montgomery P, Ben-David U, Garvie CW, Chen Y, Rees MG, Lyons NJ, McFarland JM, Wong BT, Wang L, Dumont N, O'Hearn PJ, Stefan E, Doench JG, Harrington CN, Greulich H, Meyerson M, Vazquez F, Subramanian A, Roth JA, Bittker JA, Boehm JS, Mader CC, Tsherniak A, Golub TR.
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation.
Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, Ruzek MC, Slivka PF, McGettrick AF, Banahan K, Hughes MM, Irvine AD, Fischer R, O'Neill LAJ.
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.
International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases.
Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, Brookes AJ, Brudno M, Carracedo A, den Dunnen JT, Dyke SOM, Estivill X, Goldblatt J, Gonthier C, Groft SC, Gut I, Hamosh A, Hieter P, Höhn S, Hurles ME, Kaufmann P, Knoppers BM, Krischer JP, Macek M, Matthijs G, Olry A, Parker S, Paschall J, Philippakis AA, Rehm HL, Robinson PN, Sham PC, Stefanov R, Taruscio D, Unni D, Vanstone MR, Zhang F, Brunner H, Bamshad MJ, Lochmüller H.
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS.
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis.
Chen PY, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, Gujja S, Cilfone NA, Kauffman KJ, Sun L, Sun H, Zhang X, Aryal B, Canfran-Duque A, Liu R, Kusters P, Sehgal A, Jiao Y, Anderson DG, Gulcher J, Fernandez-Hernando C, Lutgens E, Schwartz MA, Pober JS, Chittenden TW, Tellides G, Simons M.
SARM1 is a metabolic sensor activated by an increased NMN/NAD<sup>+</sup> ratio to trigger axon degeneration.
Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, Malde AK, Jia X, Luo Z, Saikot FK, Mosaiab T, Masic V, Holt S, Hartley-Tassell L, McGuinness HY, Manik MK, Bosanac T, Landsberg MJ, Kerry PS, Mobli M, Hughes RO, Milbrandt J, Kobe B, DiAntonio A, Ve T.
BIOSECURE Risk
Under active congressional scrutiny and explicitly targeted in original BIOSECURE Act drafts. All core business units provide CDMO/CRO services that could trigger restrictions. Genomics subsidiary creates additional exposure.
Key Exposures:
- •All subsidiaries provide CDMO/CRO services
- •WuXi AppTec Genomics provides gene synthesis services
- •Extensive US biotech client base creates systemic exposure
- •Named in original House BIOSECURE Act draft
Mitigation: Spun off ADC business (WuXi XDC) in November 2023, likely as pre-emptive isolation strategy. May be developing non-China manufacturing capabilities but no major restructuring announced.
BD Intelligence
Therapeutic Areas:
Recent Deals: Primarily service provider rather than asset out-licensing. Recent WuXi XDC spinoff suggests focus on protecting high-value ADC capabilities from regulatory risk.
Approach: Approach with caution due to BIOSECURE risk. Any engagement should include detailed regulatory risk assessment and contingency planning for potential BCC designation. Consider alternative non-China CDMOs for critical programs.
Red Flags
- ⚠Active congressional targeting in BIOSECURE Act discussions
- ⚠All core businesses fall under potential CDMO/CRO restrictions
- ⚠Genomics subsidiary creates additional regulatory exposure
- ⚠Complex offshore holding structure may complicate compliance
- ⚠Heavy dependence on US biotech clients creates systemic risk
Quick Facts
- Key People
- 3
- Subsidiaries
- 16
- CDMO/CRO Subs
- 16
- Genomics Subs
- 1
- Direct BIOSECURE
- 16
- Corp Events
- 4
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 10
- Drug Molecules
- 0
- Relationships
- 14
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (10 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.